Publicaciones en las que colabora con Pablo Sarobe Ugarriza (29)

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination

    Frontiers in Immunology, Vol. 13

  2. TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity

    Cancer Letters, Vol. 528, pp. 45-58

2017

  1. Expansion of tumor-infiltrating CD8+ T cells expressing PD-1 improves the efficacy of adoptive T-cell therapy

    Cancer Research, Vol. 77, Núm. 13, pp. 3672-3684

  2. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination

    Oncotarget, Vol. 8, Núm. 2, pp. 2659-2671

2016

  1. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance

    Journal of Medical Virology, Vol. 88, Núm. 5, pp. 843-851

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  2. Inhibition of FOXP3/NFAT interaction enhances T cell function after TCR stimulation

    Journal of Immunology, Vol. 195, Núm. 7, pp. 3180-3189

2014

  1. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection

    Journal of Hepatology, Vol. 60, Núm. 3, pp. 482-489

  2. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes

    Gut, Vol. 63, Núm. 4, pp. 665-673

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

2011

  1. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors

    Cancer Research, Vol. 71, Núm. 9, pp. 3214-3224

  2. Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells

    Hepatology, Vol. 54, Núm. 1, pp. 28-37

  3. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

  4. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

    Hepatology, Vol. 53, Núm. 1, pp. 23-31

  5. Induction of monocyte chemoattractant protein-1 and interleukin-10 by TGFβ1 in melanoma enhances tumor infiltration and immunosuppression

    Cancer Research, Vol. 71, Núm. 3, pp. 812-821

  6. Therapeutic effect of a peptide inhibitor of TGF-β on pulmonary fibrosis

    Cytokine, Vol. 53, Núm. 3, pp. 327-333

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

  2. Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis

    Vaccine, Vol. 28, Núm. 44, pp. 7146-7154

2009

  1. Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein

    Journal of Hepatology, Vol. 51, Núm. 3, pp. 520-527